Investment
Features
FeesSafety
Academy
More
Pluang+

Sun Summit reports up to 99% gold recovery in metallurgical tests at JD Project, BC, advancing resource estimate plans.

Market News
19 Oct 2026
Newsfile Corp
View Source
Bullish
Sun Summit reports up to 99% gold recovery in metallurgical tests at JD Project, BC, advancing resource estimate plans.

Sun Summit Minerals announced positive metallurgical test results from its JD Project in British Columbia, showing gold recoveries up to 99% using conventional extraction methods like gravity, flotation, and cyanidation. These results indicate the gold is free milling with coarse free gold, suggesting efficient processing and potential cost savings. The tests support advancing toward an inaugural Mineral Resource Estimate expected in Q1 2027, with future work focusing on optimizing grind size and flowsheet development to reduce costs and improve recovery further.

Sun Summit's positive metallurgical test results for the JD Project provide context for readers interested in mining developments. For readers following the Basic Materials sector, here is Pluang's market snapshot as of Oct 19, 2026 17:11 WIB: out of 83 priced US stocks, 42 rose and 27 fell. Notable movers include SSL (Sasol Ltd. American Depositary Shares) at USD 16.00 with a -2.08% change and a typical hold time of 3 days, MP (MP Materials) at USD 40.84 with a +1.67% change and a typical hold time of 16 days, and CENX (Century Aluminum Company Common Stock) at USD 35.59 with a +1.60% change and a typical hold time of 1 day.

More News

Lexeo Therapeutics to host event on clinical measures in PKP2 arrhythmogenic cardiomyopathy

Lexeo Therapeutics to host event on clinical measures in PKP2 arrhythmogenic cardiomyopathy

Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...

Others
Neutral
42 minutes ago
EyePoint's DURAVYU misses primary endpoint in wet AMD trial but shows reduced treatment burden and safety.

EyePoint's DURAVYU misses primary endpoint in wet AMD trial but shows reduced treatment burden and safety.

EyePoint announced that its DURAVYU treatment for wet age-related macular degeneration (wet AMD) did not meet the primary goal of matching the visual improvement of the standard aflibercept treatment in the LUCIA Phase 3 trial. However, DURAVYU demon...

Company Fundamentals
Neutral
42 minutes ago
Marker Therapeutics wins $2.6M FDA grant to advance MT-601 therapy for pancreatic cancer.

Marker Therapeutics wins $2.6M FDA grant to advance MT-601 therapy for pancreatic cancer.

Marker Therapeutics has been awarded a $2.6 million grant from the FDA's Orphan Products Clinical Trials program to support a Phase 1 study of its MT-601 multi-antigen recognizing T cell therapy for locally advanced unresectable pancreatic cancer. Th...

Market News
Bullish
42 minutes ago
Agility Robotics appoints Mark Vale as audit committee chair ahead of public listing.

Agility Robotics appoints Mark Vale as audit committee chair ahead of public listing.

Agility Robotics announced that Mark Vale, former UPS president and current CEO of Transportation Insight, will join its board and chair the audit committee after its merger with Churchill Capital Corp XI. Vale's extensive experience in global logist...

Company Fundamentals
Bullish
42 minutes ago
JazzCash wins Silver Award for innovation in InsurTech at Money20/20 USA 2026

JazzCash wins Silver Award for innovation in InsurTech at Money20/20 USA 2026

JazzCash, Pakistan's leading digital financial services platform, won the Silver Award in the Banking – InsurTech category at Money20/20 USA 2026 for its health-protection platform Sehat+. This platform provides affordable health insurance to Pakista...

Market News
Bullish
42 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App